Correlation Between Aerovate Therapeutics and Sutro Biopharma

Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Sutro Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Sutro Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aerovate Therapeutics and Sutro Biopharma, you can compare the effects of market volatilities on Aerovate Therapeutics and Sutro Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Sutro Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Sutro Biopharma.

Diversification Opportunities for Aerovate Therapeutics and Sutro Biopharma

0.49

Correlation Coefficient

Aerovate Therapeutics  Sutro Biopharma

Very weak diversification

The 3 months correlation between Aerovate and Sutro is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Sutro Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sutro Biopharma and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Sutro Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sutro Biopharma has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Sutro Biopharma go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and Sutro Biopharma

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 0.27 times more return on investment than Sutro Biopharma. However, Aerovate Therapeutics is 3.68 times less risky than Sutro Biopharma. It trades about 0.01 of its potential returns per unit of risk. Sutro Biopharma is currently generating about -0.17 per unit of risk. If you would invest  253.00  in Aerovate Therapeutics on December 20, 2024 and sell it today you would lose (1.00) from holding Aerovate Therapeutics or give up 0.4% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Aerovate Therapeutics  vs.  Sutro Biopharma

Aerovate Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aerovate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Aerovate Therapeutics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Sutro Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sutro Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Aerovate Therapeutics and Sutro Biopharma

The main advantage of trading using opposite Aerovate Therapeutics and Sutro Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Sutro Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will offset losses from the drop in Sutro Biopharma's long position.

The idea behind Aerovate Therapeutics and Sutro Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.